Proceedings of the 2000 American Control Conference. ACC (IEEE Cat. No.00CH36334) 2000
DOI: 10.1109/acc.2000.879215
|View full text |Cite
|
Sign up to set email alerts
|

Control system architecture for mechanical cardiac assist devices

Abstract: Among the medical device therapies for end-stage heart disease are ventricular assist devices that work in conjunction with a diseased heart. The control of ventricular assist devices (VADs) is an intriguing and challenging engineering problem due t o the complexity of the combined cardiovascular/VAD "plant," and the importance of reliable and high-performance control algcrithms. In this paper we present an overview of control architecture issues in cardiac assist systems relating to actuator and sensor placem… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2001
2001
2021
2021

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 1 publication
(1 reference statement)
0
2
0
Order By: Relevance
“…RBPs have been developed since the 1980s and have become more and more popular because of its small size, low cost, and potentially long working life. Those pumps have been used successfully for short term (less than 2 years typically) as a bridge to heart transplant (Paden et al 2000) at a constant pump speed. The long-term use of rotary blood pumps is expected to benefit end-stage CHF patients to a greater level, as a destination therapy or bridge-to-recovery device.…”
Section: Introductionmentioning
confidence: 99%
“…RBPs have been developed since the 1980s and have become more and more popular because of its small size, low cost, and potentially long working life. Those pumps have been used successfully for short term (less than 2 years typically) as a bridge to heart transplant (Paden et al 2000) at a constant pump speed. The long-term use of rotary blood pumps is expected to benefit end-stage CHF patients to a greater level, as a destination therapy or bridge-to-recovery device.…”
Section: Introductionmentioning
confidence: 99%
“…Currently, AHPs have been used successfully for short term (less than 2 years) as a bridge to heart transplant [3] with a constant pump speed. The long-term use of AHPs is expected to benefit end-stage CHF patients much more, especially those who are not eligible for a transplant.…”
Section: Introductionmentioning
confidence: 99%